OPTIMISE-CKD Study_Dapagliflozin effectiveness in CKD
Study identifier:D169AR00037
ClinicalTrials.gov identifier:NCT07450820
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
A multinational, observational, retrospective, secondary data study analyzing Dapagliflozin effectiveness in routine clinical practice among patients with chronic kidney disease. Local adaptation for Spain. Part 2
Medical condition
Chronic Kidney Disease
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Estimated Enrollment
14308
Study type
Observational
Age
18 Years - 130 Years
Date
Study Start Date: 18 Feb 2026
Estimated Primary Completion Date: 09 Feb 2027
Estimated Study Completion Date: 09 Feb 2027
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Apr 2026 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Other
No locations available
| Arms | Assigned Interventions |
|---|---|
| Cohort of patients treated with Dapagliflozin 10 mg Cohort of patients treated with Dapagliflozin 10 mg. Patients who start treatment with Dapagliflozin after meeting the inclusion criteria. The first prescription of Dapagliflozin 10 mg will be considered as the index date. | - |
| Comparator cohort without specific treatment for CKD other than RASi Patients who do not receive Dapagliflozin, but who meet the inclusion criteria and have RASi as CKD treatment or no specific treatment for CKD other than RASi. The index date will be matched with that of your Dapagliflozin-treated counterpart, within a ±10-day window. | - |
